Growing a pharma business requires a strategic approach considering the specific context of your company and the pharmaceutical industry as a whole. Here are some general pointers to get you started: Market and Customer: Identify your target customer: Deeply understand the specific needs and challenges of your target audience, whether it's doctors, patients, hospitals, or other healthcare providers. This helps tailor your products, services, and marketing efforts. Focus on unmet needs: Look for gaps in the market where existing solutions are inadequate or unavailable. Addressing unmet needs can give you a competitive edge and drive innovation. Track market trends: Stay updated on regulatory changes, technological advancements, and emerging diseases to adapt your approach and anticipate future opportunities. Products and Services: Invest in R&D: Develop innovative products or differentiate existing ones through unique formulations, delivery methods, or combinations. Remember ...
Schedules: Schedule A, Schedule B, Schedule C, Schedule D, Schedule E1, Schedule F, Schedule G, Schedule H, Schedule H1, Schedule I, Schedule J, Schedule K, Schedule L1, Schedule M, Schedule M1, Schedule M2, Schedule M3, Schedule N, Schedule O, Schedule P, Schedule Q, Schedule R, Schedule S, Schedule T, Schedule U, Schedule V, Schedule W, Schedule X, Schedule Y
Schedule Y describes the requirements and guidelines for permission to import and / or manufacture of new drugs for sale or to undertake clinical trials.
1.
Application for Permission
2.
Clinical Trial
I.
Approval for clinical trial
II.
Responsibilities of Sponsor
III.
Responsibilities of the Investigator(s)
IV.
Informed Consent
V.
Responsibilities of the Ethics Committee
VI.
Human Pharmacology (Phase I)
VII.
Therapeutic exploratory trials (Phase II)
VIII.
Therapeutic confirmatory trials (Phase III)
IX.
Post Marketing Trials (Phase IV)
3.
Studies in special populations
I.
Geriatrics
II.
Paediatrics
III.
Pregnant or nursing women
IV.
Post Marketing Surveillance
V.
Special studies: Bioavailability /
Bioequivalence Studies
Appendix I: Data to be submitted along with the application to conduct clinical trials/import/manufacture of new drugs for marketing in the country
Appendix IA: Data required to be submitted by an applicant for grant of permission to import and / or manufacture a new drug already approved in the country
Appendix IB: Data to be submitted along with application to conduct clinical trial or import or manufacture of a phytopharmaceutical drug in the country
Appendix II: Structure, contents and format for clinical study reports
Appendix III: Animal toxicology (non-clinical toxicity studies)
Appendix IV: Animal Pharmacology
Appendix V: Informed Consent
Appendix VI: Fix Dose Combinations (FDCs)
Appendix VII: Undertaking by Investigator
Appendix VIII: Ethics Committee
Appendix IX: Stability Testing of New Drugs
Appendix X: Contents of the proposed protocol for conducting clinical trials
Appendix XI: Data Elements for reporting serious adverse events occuring in a clinical trial
Appendix XII: Compensation in case of injury or death during clinical trial
For more detail refer Drug and Cosmetic Act
Comments
Post a Comment